IGF1 and acromegaly: Current clinical guidelines emphasise a personalised approach to acromegaly management, considering factors such as patient preferences (e.g., oral vs. injectable formulations), comorbid conditions (e.g., type 2 diabetes mellitus), disease-specific features (e.g., MRI findings, degree of IGF-1 elevation), and the potential adverse effects of therapy (e.g., hyperglycaemia).